Free Trial
CVE:MPH

Medicure 4/8/2024 Earnings Report

Medicure logo
C$1.06 +0.12 (+12.77%)
As of 05/27/2025 11:29 AM Eastern

Medicure EPS Results

Actual EPS
-C$0.14
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Medicure Revenue Results

Actual Revenue
$5.07 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Medicure Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Medicure Earnings Headlines

Man who predicted $100K Bitcoin sees a huge run coming for another coin …
Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election … surpassing $100,000 on Dec. 8 .… Now Juan believes it could hit $150,000 … or higher in 2025.
Medicure Inc. (NGQ1.F)
Medicure Inc. (MPH.V)
See More Medicure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Medicure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Medicure and other key companies, straight to your email.

About Medicure

Medicure (CVE:MPH), a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.

View Medicure Profile

More Earnings Resources from MarketBeat